MX2020006434A - Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). - Google Patents

Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).

Info

Publication number
MX2020006434A
MX2020006434A MX2020006434A MX2020006434A MX2020006434A MX 2020006434 A MX2020006434 A MX 2020006434A MX 2020006434 A MX2020006434 A MX 2020006434A MX 2020006434 A MX2020006434 A MX 2020006434A MX 2020006434 A MX2020006434 A MX 2020006434A
Authority
MX
Mexico
Prior art keywords
mtor inhibitor
inhibitor compounds
novel
novel mtor
compositions
Prior art date
Application number
MX2020006434A
Other languages
English (en)
Inventor
Laurence Clary
Gilles Ouvry
Etienne Thoreau
Jean-François Fournier
Yushma Bhurruth-Alcor
Loïc Tomas
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of MX2020006434A publication Critical patent/MX2020006434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención se relaciona con nuevos compuestos inhibidores de mTOR. Se caracteriza porque los compuestos inhibidores de mTOR son de la fórmula general (I). También se relaciona con composiciones que los comprenden, sus métodos de preparación y sus usos en composiciones como medicamento.
MX2020006434A 2017-12-21 2018-12-20 Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). MX2020006434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1771407A FR3075794A1 (fr) 2017-12-21 2017-12-21 Nouveaux composes inhibiteurs de mtor
PCT/EP2018/086066 WO2019122059A1 (fr) 2017-12-21 2018-12-20 Nouveaux composes inhibiteurs de mtor

Publications (1)

Publication Number Publication Date
MX2020006434A true MX2020006434A (es) 2020-09-17

Family

ID=61750393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006434A MX2020006434A (es) 2017-12-21 2018-12-20 Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).

Country Status (16)

Country Link
US (1) US11731973B2 (es)
EP (1) EP3727389B1 (es)
JP (1) JP7307072B2 (es)
KR (1) KR20200103031A (es)
CN (1) CN111918653A (es)
AU (1) AU2018391799B2 (es)
BR (1) BR112020012218A2 (es)
CA (1) CA3086269A1 (es)
CL (1) CL2020001687A1 (es)
FR (1) FR3075794A1 (es)
IL (1) IL275532B2 (es)
MX (1) MX2020006434A (es)
RU (1) RU2020123900A (es)
SA (1) SA520412290B1 (es)
SG (1) SG11202005870RA (es)
WO (1) WO2019122059A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
WO2023285926A1 (en) 2021-07-12 2023-01-19 Galderma Holding SA Synthesis of chiral substituted pyrazolopyrimidine compounds
WO2023031738A1 (en) 2021-08-31 2023-03-09 Galderma Holding SA Novel mtor inhibitor compounds
WO2023199196A1 (en) * 2022-04-12 2023-10-19 Galderma Holding SA Salts for mtor compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414533A (pt) * 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
JP5335432B2 (ja) 2005-11-17 2013-11-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 縮合２環系ｍＴＯＲ阻害剤
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EA018144B1 (ru) 2008-03-19 2013-05-30 Оси Фармасьютикалз, Инк. СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
TWI592411B (zh) * 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US20140357651A1 (en) 2011-05-04 2014-12-04 Yi Liu Combination pharmaceutical compositions and uses thereof
CA2835197A1 (en) 2011-05-06 2012-11-15 Intellikine Llc Treatment of polycystic disease
CA2833701A1 (en) 2013-11-19 2015-05-19 Pharmascience Inc. Protein kinase inhibitors
US20150291606A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
FR3075794A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor

Also Published As

Publication number Publication date
SG11202005870RA (en) 2020-07-29
IL275532B1 (en) 2023-05-01
US11731973B2 (en) 2023-08-22
SA520412290B1 (ar) 2022-11-25
IL275532A (en) 2020-08-31
JP7307072B2 (ja) 2023-07-11
IL275532B2 (en) 2023-09-01
US20200317679A1 (en) 2020-10-08
AU2018391799B2 (en) 2023-05-18
EP3727389A1 (fr) 2020-10-28
JP2021506918A (ja) 2021-02-22
RU2020123900A (ru) 2022-01-21
FR3075794A1 (fr) 2019-06-28
CA3086269A1 (en) 2019-06-27
BR112020012218A2 (pt) 2020-11-24
CN111918653A (zh) 2020-11-10
WO2019122059A1 (fr) 2019-06-27
AU2018391799A1 (en) 2020-07-09
EP3727389B1 (fr) 2023-05-03
KR20200103031A (ko) 2020-09-01
CL2020001687A1 (es) 2020-11-27
RU2020123900A3 (es) 2022-02-17

Similar Documents

Publication Publication Date Title
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2016002794A (es) Compuestos antiproliferativos.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
GEP201706725B (en) Compounds and compositions as inhibitors of mek
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
PH12017500737B1 (en) Kcnq2-5 channel activator
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.